REV3L Antibody

What is REV3L and why is it important in research?

REV3L is the catalytic subunit of DNA polymerase zeta (Polζ), an error-prone polymerase specialized in translesion DNA synthesis (TLS). It lacks intrinsic 3'-5' exonuclease activity and therefore has no proofreading function . This protein plays crucial roles in DNA replication and repair processes, making it significant for understanding genomic stability mechanisms. REV3L appears to be ubiquitously expressed in both normal and malignant human tissues, though its expression levels vary across different cell types . Its importance in research stems from its involvement in cellular responses to DNA-damaging agents, particularly cisplatin, making it a potential target for modulating chemosensitivity in cancer treatment.

What are the common applications for REV3L antibodies in molecular biology research?

REV3L antibodies are widely used in several molecular biology applications:

• Western Blotting (WB): For detecting and quantifying REV3L protein expression in cell and tissue lysates .

• Immunohistochemistry (IHC): Both paraffin-embedded (IHC-P) and frozen sections (IHC-F) can be analyzed to determine REV3L expression patterns in tissues .

• Immunofluorescence (IF): Used for cellular localization studies, with applications in cell cultures (ICC) and tissue sections .

• ELISA: For quantitative measurement of REV3L levels in biological samples .

These applications enable researchers to investigate REV3L expression, localization, and function in various experimental contexts, particularly in cancer research and DNA damage response studies.

What are the key specifications to consider when selecting a REV3L antibody?

When selecting a REV3L antibody for research, consider these critical specifications:

Select antibodies validated specifically for your application and species of interest, as performance can vary significantly across different experimental contexts. Consider also the targeted region of REV3L, as antibodies targeting different domains may yield varying results depending on protein conformation or isoform expression.

How should REV3L antibodies be optimized for immunohistochemistry in cancer tissue samples?

For optimal immunohistochemistry results with REV3L antibodies in cancer tissues:

• Antibody selection: Choose antibodies specifically validated for IHC-P or IHC-F depending on your sample preparation. For example, antibody bs-19840R has been validated for both IHC-P (1:200-400 dilution) and IHC-F (1:100-500 dilution) .

• Antigen retrieval optimization: Since REV3L is a nuclear protein , ensure proper nuclear antigen accessibility. Test both heat-induced epitope retrieval methods (citrate buffer pH 6.0 and EDTA buffer pH 9.0) to determine optimal conditions.

• Antibody titration: Perform a dilution series test (e.g., 1:100, 1:200, 1:400) to identify the optimal antibody concentration that maximizes specific signal while minimizing background. Starting dilutions for IHC-P are typically 1:200-400 .

• Controls: Include both positive controls (tissues known to express REV3L, such as cervical cancer tissues which show higher expression than normal tissues ) and negative controls (primary antibody omission and isotype controls).

• Signal detection system: For weakly expressed targets, consider signal amplification systems like polymer-based detection kits or tyramide signal amplification.

• Counterstaining: Use appropriate nuclear counterstains (hematoxylin) to confirm nuclear localization of REV3L.

When interpreting results, remember that REV3L expression has been observed to be higher in cervical cancer tissues compared to normal tissues , which can serve as a reference point for expected expression patterns.

What are the most effective approaches for knocking down REV3L expression in experimental studies?

Based on successful approaches documented in research:

• shRNA-mediated knockdown: Use retroviral vectors like pBABE/U6/Puro expressing REV3L-specific shRNA. One effective shRNA sequence targets: 5'-GGAGAATAGAACTATGGTGCA-3' as reported in cervical cancer studies . Establish stable cell lines through puromycin selection (200 ng/mL for 10-14 days).

• siRNA transient knockdown: For short-term experiments, transfect cells with siRNA duplexes targeting conserved regions of REV3L mRNA. Optimize transfection conditions for each cell line.

• CRISPR-Cas9 gene editing: For complete knockout studies, design guide RNAs targeting early exons of REV3L. Note that complete REV3L knockout may affect cell viability in some cancer cell lines, as REV3L inhibition alone can induce persistent DNA damage and growth arrest .

• Validation of knockdown efficiency:

  • RT-qPCR using primers such as: Forward 5'-CGCGTCAGTTGGGACTTAAG-3' and Reverse 5'-ACTATCGCCAACCTCAATGC-3'

  • Western blot with antibodies specific to REV3L

  • Functional assays to confirm biological effects of REV3L depletion

• Controls: Always include appropriate controls (e.g., shGFP or scrambled sequences) to account for non-specific effects of the knockdown procedure itself .

When designing these experiments, consider that REV3L knockdown may sensitize cells to cisplatin and other DNA-damaging agents, potentially affecting cell viability even without treatment .

How can REV3L antibodies be effectively used in studies investigating cancer chemosensitivity?

For REV3L antibody use in chemosensitivity studies:

• Baseline expression profiling:

  • Use IHC to determine REV3L expression in patient tumor samples before treatment

  • Quantify expression in cell lines using western blotting before chemotherapy exposure

  • Correlate expression levels with intrinsic chemosensitivity

• Monitoring expression changes during treatment:

  • Establish time-course experiments measuring REV3L levels after cisplatin exposure

  • Use western blotting with REV3L antibodies to detect changes in protein levels

  • Combine with RT-qPCR to correlate protein with mRNA expression changes

• Mechanistic studies:

  • Use REV3L antibodies in immunoprecipitation to identify interaction partners (e.g., MAD2L2) that form functional Polζ complexes

  • Combine with antibodies against apoptosis markers (Bcl-2, Mcl-1, Bcl-xl, and Bax) to correlate REV3L expression with apoptotic response

  • Perform chromatin immunoprecipitation with REV3L antibodies to identify genomic binding sites after DNA damage

• Functional validation:

  • Compare cisplatin sensitivity between REV3L-depleted and control cells using cell viability assays

  • Measure apoptosis rates using flow cytometry in cells with varying REV3L expression levels

  • Assess DNA damage persistence using γH2AX staining in combination with REV3L expression analysis

Research has shown that suppression of REV3L enhances sensitivity to cisplatin in cervical cancer cells, while overexpression confers resistance, correlating with changes in apoptosis rates and expression of apoptosis-related proteins . This makes REV3L a potential biomarker for predicting chemotherapy response and a promising target for enhancing chemosensitivity.

How does REV3L expression correlate with cancer prognosis, and what methodological approaches best reveal this relationship?

REV3L expression has emerging prognostic significance in cancer, particularly in relation to chemotherapy resistance. A comprehensive approach to investigating this relationship includes:

Evidence suggests that Polζ expression can function as a predictor of poor prognosis in cervical cancer patients, potentially due to chemoresistance mechanisms . Research has shown that high REV3L expression correlates with decreased sensitivity to cisplatin and related to altered apoptotic protein expression (Bcl-2, Mcl-1, Bcl-xl, and Bax) . These findings support REV3L's role as both a prognostic biomarker and potential therapeutic target.

What are the mechanisms by which REV3L affects cell cycle progression, and how can this be effectively studied?

REV3L has been implicated in cell cycle regulation, particularly affecting G1-to-S phase transition. To study these mechanisms:

• Cell cycle analysis methodologies:

  • Flow cytometry with propidium iodide staining to quantify cell cycle distribution

  • EdU incorporation assays to measure S phase entry

  • Time-lapse microscopy with cell cycle markers in REV3L-modulated cells

• Molecular mechanism investigations:

  • Immunoblotting for cell cycle regulators (cyclins, CDKs) in REV3L-depleted vs. control cells

  • Co-immunoprecipitation with REV3L antibodies to identify interactions with cell cycle proteins

  • Chromatin immunoprecipitation to determine if REV3L directly affects expression of cell cycle genes

• Checkpoint response analysis:

  • Combine REV3L modulation with checkpoint inhibitors to determine pathway dependencies

  • Measure ATR/ATM/CHK1/CHK2 activation in response to DNA damage in REV3L-modulated cells

  • Assess p53 and p21 status and their relationship to REV3L-mediated cell cycle effects

• Rescue experiments:

  • Overexpress specific cell cycle regulators in REV3L-depleted cells to identify critical downstream effectors

  • Use cell cycle synchronization methods to determine phase-specific effects of REV3L

Research has demonstrated that depletion of REV3L suppresses cell proliferation and colony formation of cervical cancer cells through G1 arrest, while REV3L overexpression promotes cell proliferation by facilitating G1-to-S phase transition . This suggests REV3L has functions beyond its known translesion synthesis role, potentially affecting cell cycle progression through direct or indirect mechanisms that warrant further investigation.

How does REV3L interact with other DNA repair pathways, and what techniques best reveal these interactions?

REV3L's interactions with other DNA repair pathways represent an important area for investigation:

• Protein-protein interaction studies:

  • Immunoprecipitation with REV3L antibodies followed by mass spectrometry to identify novel interactors

  • Proximity ligation assays to visualize interactions with known DNA repair proteins in situ

  • FRET or BiFC assays for real-time monitoring of dynamic interactions

• Pathway crosstalk analysis:

  • Combined knockdown/knockout experiments targeting REV3L alongside components of homologous recombination, non-homologous end joining, or nucleotide excision repair

  • Synthetic lethality screens to identify dependencies between REV3L and other repair pathways

  • Epistasis analysis to position REV3L within repair pathway hierarchies

• DNA damage response monitoring:

  • Comet assays to measure DNA break persistence in REV3L-modulated cells

  • Immunofluorescence for repair foci (γH2AX, RAD51, 53BP1) formation and resolution kinetics

  • DNA fiber assays to measure replication fork progression and restart after damage

• Genomic techniques:

  • ChIP-seq to map REV3L recruitment to damaged chromatin

  • CRISPR screens to identify genetic dependencies related to REV3L function

  • Mutation signature analysis to correlate REV3L status with specific mutation patterns

REV3L is known to interact with MAD2L2 to form the error-prone DNA polymerase zeta involved in translesion DNA synthesis . Research has shown that REV3L depletion can increase sensitivity to cisplatin in multiple cancer types, including mouse B-cell lymphomas, lung cancer cells, and human colon carcinoma cells . This suggests REV3L functions at the intersection of DNA damage tolerance and repair pathways, with implications for both mutagenesis and cell survival under genotoxic stress.

What are common problems when working with REV3L antibodies, and how can researchers overcome them?

Several challenges may arise when working with REV3L antibodies:

• Low signal intensity:

  • Problem: REV3L may be expressed at low levels in some tissues/cells

  • Solutions:

    • Use signal amplification systems (e.g., biotin-streptavidin, tyramide)

    • Increase antibody concentration while monitoring background

    • Extend primary antibody incubation time (overnight at 4°C)

    • Consider more sensitive detection methods (e.g., ECL Prime for western blots)

• High background:

  • Problem: Non-specific binding, particularly with polyclonal antibodies

  • Solutions:

    • Increase blocking time/concentration (5% BSA or 5% non-fat milk)

    • Add 0.1-0.3% Triton X-100 for membrane permeabilization

    • Optimize antibody dilution through titration experiments

    • Use validated antibodies with confirmed specificity (e.g., ABIN562630 , bs-19840R )

• Inconsistent results between applications:

  • Problem: Antibodies may perform differently in WB versus IHC or IF

  • Solutions:

    • Select antibodies specifically validated for your application

    • Consider the immunogen region - antibodies targeting different epitopes may yield different results

    • Test multiple antibodies targeting different regions of REV3L

    • Validate findings with complementary techniques (e.g., mRNA expression)

• Detecting specific isoforms:

  • Problem: REV3L has multiple isoforms that may not be recognized by all antibodies

  • Solutions:

    • Select antibodies with known epitopes in regions common to all isoforms

    • Use antibodies targeting specific isoform-unique regions when studying particular variants

    • Complement protein studies with isoform-specific PCR primers

Always include appropriate controls: positive controls (tissues/cells known to express REV3L, such as cervical cancer tissues ), negative controls (REV3L-depleted cells), and technical controls (primary antibody omission).

How should researchers interpret contradictory REV3L expression data across different experimental techniques?

When faced with contradictory REV3L expression data:

• Technical considerations for reconciliation:

  • Western blot vs. IHC discrepancies: Consider protein extraction efficiency, epitope accessibility in fixed tissues, and antibody performance in denatured vs. native conditions

  • mRNA vs. protein level discrepancies: May reflect post-transcriptional regulation; validate with multiple primer sets targeting different exons

  • Different antibodies showing varied results: May recognize different epitopes or isoforms; use antibodies targeting distinct regions to build a complete picture

• Biological considerations:

  • Cell type heterogeneity: In tissues, cell-specific expression may be averaged in whole-tissue lysates

  • Subcellular localization: REV3L is primarily nuclear ; incomplete extraction protocols may miss nuclear fraction

  • Dynamic expression changes: REV3L expression may change during cell cycle or in response to DNA damage

• Resolution approaches:

  • Multiple antibody validation: Test several antibodies targeting different epitopes (e.g., N-terminal vs. central region vs. C-terminal )

  • Orthogonal techniques: Combine protein detection with mRNA analysis and functional assays

  • Single-cell approaches: Use flow cytometry or single-cell sequencing to resolve heterogeneity issues

  • Controls: Include REV3L-overexpressing and REV3L-knockdown samples as benchmarks

• Quantification standardization:

  • Use consistent quantification methods across experiments

  • Normalize to appropriate housekeeping genes/proteins (e.g., GAPDH for RT-qPCR )

  • Apply statistical methods appropriate for the data distribution

In research studies, REV3L expression has been reliably detected using RT-qPCR with primers targeting specific regions (e.g., forward 5'-CGCGTCAGTTGGGACTTAAG-3' and reverse 5'-ACTATCGCCAACCTCAATGC-3' ), providing a standard approach for mRNA quantification that can help resolve contradictions.

What considerations are important when correlating REV3L expression with chemoresistance in experimental models?

When investigating REV3L and chemoresistance correlations:

Research has demonstrated that REV3L suppression enhances sensitivity to cisplatin in cervical cancer cells, while overexpression confers resistance through mechanisms involving altered apoptotic protein expression . These findings provide a methodological framework for investigating REV3L's role in chemoresistance across different cancer types and treatment regimens.

What emerging technologies might advance REV3L antibody-based research in cancer biology?

Several cutting-edge technologies hold promise for advancing REV3L research:

• Advanced imaging technologies:

  • Super-resolution microscopy to visualize REV3L localization at DNA damage sites with nanometer precision

  • Live-cell imaging with fluorescently tagged REV3L to track dynamics during DNA damage responses

  • Correlative light and electron microscopy (CLEM) to link REV3L molecular localization with ultrastructural features

• Single-cell analysis platforms:

  • Single-cell proteomics to correlate REV3L with other DNA repair proteins at individual cell level

  • CyTOF/mass cytometry with REV3L antibodies for high-dimensional analysis of heterogeneous tumor samples

  • Spatial transcriptomics combined with REV3L protein detection to map expression patterns within the tumor microenvironment

• Proximity-based interaction mapping:

  • BioID or APEX2 proximity labeling fused to REV3L to identify the complete interactome

  • FRET-based biosensors to monitor REV3L activity in real-time

  • Cross-linking mass spectrometry to capture transient interactions during DNA repair processes

• Therapeutic targeting approaches:

  • Antibody-drug conjugates targeting REV3L-overexpressing cells

  • Proteolysis-targeting chimeras (PROTACs) for selective REV3L degradation

  • RNA-based therapeutics (siRNA, antisense oligonucleotides) encapsulated in tumor-targeting nanoparticles

• Computational and AI approaches:

  • Machine learning algorithms to predict REV3L expression patterns from histopathology images

  • Integrative multi-omics analysis correlating REV3L with mutation signatures and clinical outcomes

  • Structural biology and molecular dynamics simulations to design small molecule inhibitors

These technologies could help address key knowledge gaps, such as understanding the dynamic regulation of REV3L during DNA damage responses, identifying cancer-specific vulnerabilities related to REV3L function, and developing targeted approaches to modulate REV3L activity in chemoresistant tumors.

How might REV3L antibodies be incorporated into predictive biomarker panels for cancer treatment response?

Incorporating REV3L antibodies into predictive biomarker panels:

• Multiplex IHC/IF approaches:

  • Develop validated multiplex panels including REV3L alongside other DNA repair proteins (BRCA1/2, RAD51, ERCC1)

  • Utilize multicolor immunofluorescence with spectral unmixing to quantify multiple markers simultaneously

  • Implement digital pathology algorithms for standardized quantification

  • Correlate spatial relationships between REV3L and other markers with treatment outcomes

• Liquid biopsy integration:

  • Detect REV3L in circulating tumor cells using optimized antibody-based capture methods

  • Monitor changes in REV3L expression during treatment as a dynamic response biomarker

  • Correlate with circulating tumor DNA damage signatures

• Predictive model development:

  • Train machine learning algorithms using REV3L expression data combined with other biomarkers

  • Validate in prospective clinical cohorts across multiple cancer types

  • Establish clinically relevant cutoff values for REV3L expression levels

  • Create decision support tools integrating REV3L status with other clinical parameters

• Companion diagnostic development pathway:

  • Standardize REV3L antibody-based assays with reproducible protocols

  • Validate analytical performance across multiple laboratories

  • Establish clinical utility through prospective studies

  • Pursue regulatory approval alongside targeted therapies

Research has already established that REV3L expression correlates with poor prognosis and potential chemoradiation resistance in cervical cancer patients . Expanding these findings to create comprehensive biomarker panels could significantly improve treatment stratification, particularly for platinum-based chemotherapy regimens. The development of standardized, clinically validated antibody-based assays for REV3L would be a critical step toward realizing its potential as a predictive biomarker.